Search

Study Design: Cross-sectional study., Objective: To evaluate for areas of consensus and divergence of opinion within the spine community regarding the management of cervical spondylotic conditions and acute traumatic central cord syndrome (ATCCS) and the influence of the patient's age, disease severity, and myelomalacia., Summary of Background Data: There is ongoing disagreement regarding the indications for, and urgency of, operative intervention in patients with mild degenerative myelopathy, moderate to severe radiculopathy, isolated axial symptomatology with evidence of spinal cord compression, and ATCCS without myelomalacia., Methods: A survey request was sent to 330 attendees of the Cervical Spine Research Society (CSRS) 2021 Annual Meeting to assess practice patterns regarding the treatment of cervical stenosis, myelopathy, radiculopathy, and ATCCS in 16 unique clinical vignettes with associated MRIs. Operative versus nonoperative treatment consensus was defined by a management option selected by >80% of survey participants., Results: Overall, 116 meeting attendees completed the survey. Consensus supported nonoperative management for elderly patients with axial neck pain and adults with axial neck pain without myelomalacia. Operative management was indicated for adult patients with mild myelopathy and myelomalacia, adult patients with severe radiculopathy, elderly patients with severe radiculopathy and myelomalacia, and elderly ATCCS patients with pre-existing myelopathic symptoms. Treatment discrepancy in favor of nonoperative management was found for adult patients with isolated axial symptomatology and myelomalacia. Treatment discrepancy favored operative management for elderly patients with mild myelopathy, adult patients with mild myelopathy without myelomalacia, elderly patients with severe radiculopathy without myelomalacia, and elderly ATCCS patients without preceding symptoms., Conclusions: Although there is uncertainty regarding the treatment of mild myelopathy, operative intervention was favored for nonelderly patients with evidence of myelomalacia or radiculopathy and for elderly patients with ATCCS, especially if pre-injury myelopathic symptoms were present., Level of Evidence: Level V., Competing Interests: B.C.: DePuy, A Johnson & Johnson Company: IP royalties, SpinologyTenex: Stock or stock options, Surgalign: paid consultant, Wolters Kluwer Health-Lippincott Williams & Wilkins: publishing royalties, financial or material support, Zimmer: IP royalties. B.A.F.: Ankasa: research support, AO Spine: paid presenter or speaker, Clear Choice Therapeutics: stock or stock options, Kuros: paid consultant, Medtronic: paid consultant; research support, Neuroinnovations: stock or stock options, Synthes: paid consultant, Theradaptive: paid consultant. A.N.N.: American Orthopaedic Association: Board or committee member, AO Spine: research support, Cervical Spine Research Society: Board or committee member, Lumbar Spine Research Society: Board or committee member, Pfizer: research support, Premia Spine: research support, Scoliosis Research Society: Board or committee member, Techniques in Orthopedics: editorial or governing board. B.A.K.: Clinical Spine Surgery: editorial or governing board. A.S.S.: Cerapedics: paid consultant; paid presenter or speaker, CTL Amedica: IP royalties, DePuy, A Johnson & Johnson Company: paid consultant, Jaypee Publishers: IP royalties. J.M.R.: Alphatec Spine: paid consultant; paid presenter or speaker, Biomet: IP royalties, Cervical Spine Research Society: Board or committee member, Medtronic: paid presenter or speaker, Stryker: IP royalties; paid presenter or speaker, Wolters Kluwer Health-Lippincott Williams & Wilkins: publishing royalties, financial or material support, Zimmer: paid presenter or speaker. M.G.F.: Neuraxis: paid consultant. The remaining authors declare no conflict of interest., (Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.)